Scientists at Mologic were part of a recent publication looking at the feasibility of using lyophilised recombinant human G6PD as a QC reagent in novel point-of-care tests for G6PD deficiency.

Find out more here or click on the image:


Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care.

Our Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test. Launched in 1988, it was the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.